These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35989895)

  • 1. Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.
    Shakeri A; Hayes KN; Gomes T; Tadrous M
    Can Liver J; 2021; 4(4):426-429. PubMed ID: 35989895
    [No Abstract]   [Full Text] [Related]  

  • 2. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.
    Tadrous M; Mason K; Dodd Z; Guyton M; Powis J; McCormack D; Gomes T
    Can Liver J; 2021; 4(1):51-58. PubMed ID: 35991476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET
    Hasegawa T; Sawada S; Ishiguro C; Ando T; Kobayashi K; Komiyama N; Iguchi T; Nonaka T; Uyama Y
    Ther Innov Regul Sci; 2022 Jul; 56(4):625-631. PubMed ID: 35437631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
    Myers S; Khosa G; Kuo IF; Janzen D; Alessi-Severini S
    J Pharm Pharm Sci; 2018; 21(1s):271s-308s. PubMed ID: 30407908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment.
    Kida F; Murayama A; Saito H; Ozaki A; Shimada Y; Tanimoto T
    Liver Int; 2021 Mar; 41(3):464-469. PubMed ID: 33306236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.
    Raza MN; Sughra K; Zeeshan N; Anwar MZ; Shahzad MA; Rashid U; Afroz A; Munir H
    Braz J Biol; 2021; 83():e252610. PubMed ID: 34909837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
    Chen JH; Wu PN; Huang SC; Hsu PJ; Hsu JC
    Curr Med Res Opin; 2021 Feb; 37(2):245-252. PubMed ID: 33251875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
    J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.
    Uddin R; Jalal K; Khan K; Ul-Haq Z
    J Mol Struct; 2022 Feb; 1250():131920. PubMed ID: 34815586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada.
    Konstantelos N; Shakeri A; McCormack D; Feld JJ; Gomes T; Tadrous M
    Am J Gastroenterol; 2021 Aug; 116(8):1738-1740. PubMed ID: 34587128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J; He T; Hur C; Lopez-Olivo MA
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
    Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
    AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
    J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.
    Liu CH; Lee MH; Lin JW; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Hepatol; 2020 May; 72(5):839-846. PubMed ID: 31790766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.